<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287179</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4650</org_study_id>
    <secondary_id>U1111-1242-5426</secondary_id>
    <secondary_id>2019-004234-42</secondary_id>
    <nct_id>NCT04287179</nct_id>
  </id_info>
  <brief_title>SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes</brief_title>
  <acronym>SUSTAIN SWITCH</acronym>
  <official_title>Effect and Safety of Two Different Dose-escalation Regimens for Once-weekly Semaglutide s.c. in Subjects With Type 2 Diabetes Mellitus Previously Treated With GLP-1 RAs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect and safety of 2 dose schedules for semaglutide (study
      medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar
      to semaglutide. The study will also evaluate the use of a new pen-injector for semaglutide
      used to inject medicine under the skin, at a new dose of 2 mg. People taking part in the
      study will take this medicine together with their current diabetes tablets other than
      semaglutide. Participants will either get a start dose of 0.25 mg semaglutide or 0.50 mg
      semaglutide, and the dose will be gradually increased to 2.0 mg semaglutide - which treatment
      is decided by chance. Participants will inject semaglutide under the skin once a week, any
      time of the day. When the dose reaches 2.0 mg semaglutide, participants will inject the
      medicine with a new type of pen-injector. The study will last for about 24 weeks.
      Participants will have 9 visits and 1 phone call with the study doctor. At 9 visits
      participants will have blood taken and at 2 visits they will have eye examination done. Women
      cannot take part if pregnant, breast-feeding or planning to become pregnant during the study
      period. Women who are able to get pregnant will be checked 10 times for pregnancy via urine
      tests.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">January 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Percent-point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent gastrointestinal adverse events</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse rate</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Beats per minute (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From week 12 to week 17</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide 0.50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 0.25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.</description>
    <arm_group_label>Semaglutide 0.25 mg</arm_group_label>
    <arm_group_label>Semaglutide 0.50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18 years or older at the time of signing informed consent.

          -  Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of
             screening.

          -  The need and willingness to change prior GLP-1 RA treatment to once-weekly semaglutide
             s.c., as assessed by the investigator.

          -  HbA1c of 6.5-10% (48−86 mmol/mol) (both inclusive).

          -  Treatment with any therapeutic dose of GLP-1 RA other than once-weekly semaglutide
             s.c., as defined in the local label, with or without OADs (metformin, DPP-4 inhibitor,
             SU, glinide, thiazolidinedione, SGLT-2 inhibitor or alpha-glucosidase inhibitor). All
             doses of antidiabetic treatments should have been stable for at least 90 days prior to
             the day of the screening, at investigator's discretion.

        Exclusion Criteria:

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria within the past 90 days prior to the day of
             screening. However, short term insulin treatment for a maximum of 14 days prior to the
             day of screening is allowed, as is prior insulin treatment for gestational diabetes.

          -  Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less
             than 30 mL/min/1.73 m2 according to Chronic Kidney Disease Epidemiology Collaboration
             (CKDEPI) creatinine equation as defined by KDIGO 2012 classification.

          -  Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by
             a fundus examination performed within the past 90 days prior to screening or in the
             period between screening and randomisation. Pharmacological pupil-dilation is a
             requirement unless using a digital fundus photography camera specified for non-dilated
             examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor &amp; Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404-7596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockerau</city>
        <zip>2000</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Raisio</city>
        <zip>21200</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials. com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

